PressApril 17, 2024 Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
PressApril 17, 2024 Cedar Clinical Research selected as clinical research site for Cybin’s Phase 3 Study of CYB003
PressApril 16, 2024 Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
PressApril 16, 2024 PharmaDrug’s SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine
PressApril 16, 2024 Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
PressApril 16, 2024 Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
Market ResearchApril 12, 2024 The EU’s Plan for a €6.5M Study of Psychedelics To Treat Mental Disorders
PressApril 12, 2024 Red Light Holland’s Largest Psilocybin Shipment Received by CCrest Labs in Montreal with Health Canada Approved Import Permit
PressApril 11, 2024 Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research’s Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
PressApril 10, 2024 Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
PressApril 10, 2024 Seaport Therapeutics Launches with $100 Million Oversubscribed Series a Financing Round to Advance Novel Neuropsychiatric Medicines
PressApril 10, 2024 Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
PressApril 9, 2024 Red Light Holland Launches Its Largest Psilocybin Shipment to Canada with Health Canada Approved Import Permit; Debenture Offering Successfully Closed
